Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623944 · ClinicalTrials.gov registry record · Phase 1
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
A Phase 1 study of MDS and AML, Adult, sponsored by Nkarta.
- Active
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 8
- Study locations
NCT04623944 is a Phase 1 study of MDS and AML, Adult that is active but no longer recruiting, run by Nkarta. The registered enrollment target is 61 participants, below the 94-participant average among 22 other MDS trials with a reported enrollment target (35% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT04623944, a Phase 1 study of MDS and AML, Adult, is active but no longer recruiting, sponsored by Nkarta.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
Conditions Studied
Interventions
- BIOLOGICAL NKX101 - CAR NK cell therapy
Study Locations (8)
Texas
- MD Anderson Cancer Center, University of Texas - Houston
- Methodist Healthcare System of San Antonio - San Antonio
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Mayo Clinic Florida - Jacksonville
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Ohio
- The Cleveland Clinic - Taussig Cancer Institute - Cleveland
Tennessee
- Sarah Cannon at TriStar Bone Marrow Transplant Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2039-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623944
The ClinicalTrials.gov registry entry for NCT04623944 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 22 other MDS trials with a reported enrollment target (35% lower). The listed sponsor is Nkarta, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with MDS appearing as the primary indexed condition, and to 1 intervention - of which NKX101 - CAR NK cell therapy is the first listed.
NCT04623944 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT04623944 about?
NCT04623944 is a clinical study titled "NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS". This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.
What is the current status of trial NCT04623944?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2020-09-21. Estimated completion is 2039-07.
What conditions does trial NCT04623944 study?
This clinical trial studies the following conditions: MDS, AML, Adult, Refractory Myelodysplastic Syndromes, Relapsed/Refractory AML.
What interventions are being tested in trial NCT04623944?
The interventions under investigation include: NKX101 - CAR NK cell therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04623944?
This trial is sponsored by Nkarta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623944 being conducted?
This trial has 8 study locations across Colorado, Florida, Georgia, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.